

SeQuent Scientific Announces Q1FY19 Financial Results

Reports 70% growth in EBITDA with 21% year on year growth in revenues

Mumbai, August 9, 2018: SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & Analytical Services today announced its financial results for the quarter ended June 30, 2018 (Q1FY19)

Financial Highlights

Particulars	Q1FY19	Q1FY18	Growth (%)
Revenues	2,352	1,942	21%
EBITDA	250	147	70%
EBITDA %	10.6%	7.6%	300 bps
PAT	45	6	650+%

All values in ₹mn

Commenting on the Q1FY19 results, **Manish Gupta, Managing Director of SeQuent Scientific Limited** said: "We delivered robust growth in revenue with our improved operating leverage leading to a 300 basis point improvement in the margins. The performance would have been even better had we not witnessed the currency headwinds in Turkey (-17%) and Brazil (-10%) coupled with regulatory changes in Turkey which impacted our primary sales."

He further added "Our recent Bremer acquisition in Germany has helped us shape a valuable injectables strategy for regulated markets. With 12 API filings in US, we have the largest filings for any generic companies in US. We stay confident of delivering the strategic and financial outcomes for FY19 as our API business gains momentum and Europe gains further traction driven by ~25 new launches planned across geographies."

Detailed presentation on the performance forms part of this press release.

Earnings Call with Investors

The Company will conduct an Earnings call at **9 AM IST on August 10th, 2018** where the Management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263 or +91 22 7115 8213**.

The other numbers are listed in the conference call invite which is posted on the website of the Company.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has seven manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its API facility at Vizag is India's first and only USFDA approved facility for veterinary APIs.

The human API business of Sequent was recently demerged into Solara Active Pharma Sciences Ltd. (Solara), with an appointed date of 1st October 2017.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer

Tel: +91 22 4111 4717

tushar.m@sequent.in

Shivangi Bubna

Christensen Investor Relations

Tel : +91 22 4215 0210

sbubna@christensenir.com

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.